An AI-Assisted Agentic System for Ultrasound Scanning and Diagnosis of Ovarian Lesions
New Strategy of Knowledge-Enhanced Large Model for Ultrasound Scanning and Diagnosis of Ovarian Masses
Investigators developed an interactive agentic system designed to guide newly qualified sonographers in ovarian lesion scanning and improve their scanning quality and diagnostic performance toward expert-level standards. Our agentic system is capable of capturing key features including the max-diameter plane of ovarian lesions from dynamic ultrasound videos, translating these findings into standardized International Ovarian Tumor Analysis (IOTA) descriptors, and providing multi-turn guidance for subsequent scanning, and ultimately generating an AI-assisted diagnostic assessment based on embedded expert knowledge.
In this multicenter study, participants are asked to undergo gynecological ultrasonography performed by sonographers with less than 3 years of experience with or without AI assistance. Our researchers will compare the performance of operators working with AI against that of operators working without AI, as well as against the performance of expert sonographers, to see whether AI assistance enhances the proficiency of less experienced operators and help them approach the scanning quality and diagnostic accuracy of expert sonographers in real-world clinical scenarios.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This multicenter, prospective study will be conducted at tertiary cancer centers and primary healthcare institutions across China. Participants will be recruited from gynecological ultrasound clinics of each site.
Each participant will undergo gynecological ultrasonography under both AI-assisted and unassisted conditions according to their group allocation. Following completion of the study examinations, expert sonographers with more than 10 years of experience, blinded to the scanning and diagnostic results of the junior sonographers, will independently perform a repeat gynecological ultrasound examination of each participant. Based solely on their independent examination, they will issue the final clinical report for each participant. The expert assessments will serve as one reference standard for evaluating scanning completeness, feature interpretation accuracy and diagnostic agreement. Histopathological findings, when available, or clinical follow-up for conservatively managed lesions will serve as the reference standard for evaluating diagnostic accuracy.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jiale Qin, Prof., Professor
- Numéro de téléphone: +86 0571-89998869
- E-mail: qinjiale@zju.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Ruixia Dai, Ph.D. student
- E-mail: 12418399@zju.edu.cn
Lieux d'étude
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310006
- Women's Hospital School Of Medicine Zhejiang University
-
Contact:
- Jiale Qin, Prof., Professor
- Numéro de téléphone: +86 0571-89998869
- E-mail: qinjiale@zju.edu.cn
-
Contact:
- Ruixia Dai, Ph.D. student
- E-mail: 12418399@zju.edu.cn
-
Shaoxing, Zhejiang, Chine, 311800
- Shaoxing Maternity and Child Health Care Hospital
-
Contact:
- Hua Yuan, Chief physician in ultrasound
- Numéro de téléphone: +86 0575-88211352
- E-mail: yh0464@163.com
-
Contact:
- Xuezhen Lou, Attending physician
- E-mail: 505571621@qq.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Female aged 18-75 years
- With suspected ovarian masses identified clinically or by previous imaging examination
- Eligible for and able to undergo transvaginal or transabdominal ultrasonography
- Agree to provide written informed consent before enrollment
Exclusion Criteria:
- No ovarian mass identified on ultrasound examination
- Previous bilateral oophorectomy
- Previous surgery or chemotherapy for ovarian cancer
- Previous treatment for other malignant tumors
- Presence of any psychiatric or psychological disorders that may prevent completion of the study procedures or follow-up
- Concurrent participation in other clinical trials that may interfere with the outcomes of this study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Arm A: experimental sequence of non-AI exertion followed by AI-assisted exertion
The goal is to test the within-operator effect associated with AI assistance by comparing the performance of the same junior sonographer before and after AI guidance, and to compare the performance of both AI-assisted and unaided junior sonographers with that of the standalone AI model.
|
Participants first undergo ultrasound scanning and diagnosis by a junior sonographer without AI assistance, followed by ultrasound scanning by the same sonographer with AI assistance.
|
|
Arm B: experimental sequence of AI-assisted exertion followed by non-AI exertion
The goal is to test the clinical utility of AI with minimized potential carry-over effects and recall bias caused by repeated examinations on the same patient, by comparing the performance of one junior sonographer with AI-assisted, with that of independent unaided junior sonographers, and by comparing the performance of both AI-assisted junior sonographers and another unaided ones with that of the standalone AI model.
|
Participants first undergo ultrasound scanning and diagnosis by a junior sonographer with AI assistance, followed by ultrasound scanning by another junior sonographer without AI assistance.
The two junior sonographers are blinded to each other's scanning and assessment results.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Completeness of ultrasound feature acquisition
Délai: Up to 7 days from completion of the study
|
The completeness of ultrasound feature acquisition will be assessed with reference to national authoritative quality-control standards.
After each examination, all stored ultrasound images and videos will be labeled according to their intended purpose.
A feature will be considered adequately acquired when at least one stored image or video provides sufficient visual evidence for assessment of that feature.
The proportion of required features successfully acquired will be calculated.
The proportion of redundant stored images will also be recorded as an additional indicator of acquisition quality.
|
Up to 7 days from completion of the study
|
|
Accuracy of interpretation of individual ultrasound features
Délai: Up to 7 days from completion of the study
|
The accuracy of interpretation of ultrasound features will be assessed by comparing the assessments made by junior sonographers under AI-assisted and unassisted conditions with the findings independently acquired and interpreted by expert sonographers during a separate repeat ultrasound examination.
The accuracy rate for each feature will be calculated.
|
Up to 7 days from completion of the study
|
|
Agreement between junior and expert sonographers in ultrasound diagnosis
Délai: Up to 7 days from completion of the study
|
Agreement between junior and expert sonographers will be assessed for the final diagnosis of ovarian lesions.
The assessments made by junior sonographers under AI-assisted and unassisted conditions will be compared with the corresponding diagnoses independently obtained by expert sonographers during a separate repeat ultrasound examination, which will then be quantified using appropriate agreement statistics.
|
Up to 7 days from completion of the study
|
|
Diagnostic accuracy of ovarian tumors
Délai: Within 3 months after the ultrasonography examination
|
Diagnostic accuracy will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
|
Diagnostic performance of ovarian tumors
Délai: Within 3 months after the ultrasonography examination
|
Area under curve will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
|
Diagnostic performance of ovarian tumors
Délai: Within 3 months after the ultrasonography examination
|
Diagnostic sensitivity and specificity will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
|
Diagnostic performance of ovarian tumors
Délai: Within 3 months after the ultrasonography examination
|
Diagnostic F1-score will be assessed against histopathological diagnosis as the golden reference standard.
This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
|
Within 3 months after the ultrasonography examination
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Confidence in ultrasound feature acquisition and diagnosis
Délai: Up to 7 days from completion of the study
|
Sonographers' confidence in the completeness and adequacy of feature acquisition and in their final diagnostic assessment will be evaluated using a predefined rating scale as follows: 5 = very confident, 4 = confident, 3 = uncertain, 2 = less confident, and 1 = not confident at al.
|
Up to 7 days from completion of the study
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- IRB-20250490-R
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .